Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 17/20 | 0.55 |
| ▸ | GSK3B | P49841 | 5/20 | 0.48 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489443 | 0.88 | AKT2 (0.51) | AKT2GSK3BAKT1HCRTR1HCRTR2 | |
| SCHEMBL3490873 | 0.87 | AKT2 (0.52) | AKT2GSK3BAKT1CYP2D6CYP2C9 | |
| SCHEMBL3489749 | 0.86 | AKT2 (0.60) | AKT2GSK3BAKT1HCRTR1HCRTR2 | |
| SCHEMBL3492056 | 0.86 | AKT2 (0.46) | AKT2GSK3BAKT1CYP2D6CYP2C9 | |
| SCHEMBL3488883 | 0.85 | AKT2 (0.49) | AKT2GSK3BAKT1CYP2C9JAK3 | |
| SCHEMBL3489674 | 0.84 | AKT2 (0.50) | AKT2GSK3BAKT1CYP2D6CYP2C9 | |
| SCHEMBL3489645 | 0.84 | AKT2 (0.50) | AKT2GSK3BAKT1CYP2D6CYP2C9 | |
| SCHEMBL3489475 | 0.83 | AKT2 (0.54) | AKT2GSK3BAKT1HCRTR1HCRTR2 | |
| SCHEMBL13403214 | 0.82 | AKT2 (0.48) | AKT2GSK3BAKT1CYP2D6CYP2C9 | |
| SCHEMBL13403209 | 0.82 | AKT2 (0.54) | AKT2GSK3BAKT1CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | PRKAR2B, GRK3, PRKAR2A | AKT2 35/4885GSK3B 300/4885AKT1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.